Kyongbo Pharmaceutical Co Ltd Total Assets
Kyongbo Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) holds total assets worth ₩367.57 Billion KRW (≈ $249.10 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Kyongbo Pharmaceutical Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Kyongbo Pharmaceutical Co Ltd (2014–2025)
Total assets of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. This chart illustrates how Kyongbo Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Kyongbo Pharmaceutical Co Ltd for real-time trading data and today's change.
Kyongbo Pharmaceutical Co Ltd - Asset Composition Analysis
Kyongbo Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Kyongbo Pharmaceutical Co Ltd total assets breakdown as of December 2025. Kyongbo Pharmaceutical Co Ltd's total assets of ₩367.57 Billion consist of 49.8% current assets and 50.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.3% |
| Accounts Receivable | ₩63.27 Billion | 19.8% |
| Inventory | ₩80.98 Billion | 25.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩3.88 Billion | 1.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Kyongbo Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Kyongbo Pharmaceutical Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kyongbo Pharmaceutical Co Ltd's current assets represent 49.8% of total assets in 2025, a decrease from 58.0% in 2014.
- Cash Position: Cash and equivalents constituted 2.3% of total assets in 2025, down from 4.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 25.3% of total assets.
Kyongbo Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Kyongbo Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Kyongbo Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.88 | 0.97 | 1.32 |
| Quick Ratio | 0.48 | 0.40 | 0.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-23.65 Billion | ₩-4.42 Billion | ₩28.15 Billion |
Kyongbo Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Kyongbo Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.88 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 12.6% |
| Total Assets | ₩319.54 Billion |
| Market Capitalization | $82.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kyongbo Pharmaceutical Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Kyongbo Pharmaceutical Co Ltd's assets grew by 12.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kyongbo Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual total assets of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩319.54 Billion ≈ $216.55 Million |
+12.56% |
| 2024-12-31 | ₩283.89 Billion ≈ $192.39 Million |
+6.60% |
| 2023-12-31 | ₩266.31 Billion ≈ $180.47 Million |
+10.71% |
| 2022-12-31 | ₩240.54 Billion ≈ $163.01 Million |
+1.50% |
| 2021-12-31 | ₩236.98 Billion ≈ $160.60 Million |
-6.42% |
| 2020-12-31 | ₩253.24 Billion ≈ $171.62 Million |
+6.49% |
| 2019-12-31 | ₩237.82 Billion ≈ $161.17 Million |
+7.31% |
| 2018-12-31 | ₩221.62 Billion ≈ $150.19 Million |
+8.18% |
| 2017-12-31 | ₩204.87 Billion ≈ $138.84 Million |
+0.56% |
| 2016-12-31 | ₩203.74 Billion ≈ $138.07 Million |
+4.22% |
| 2015-12-31 | ₩195.49 Billion ≈ $132.48 Million |
+16.34% |
| 2014-12-31 | ₩168.03 Billion ≈ $113.87 Million |
-- |
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more